The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
Abstract
BACKGROUND: High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation has been reported to provide higher response rates and better overall survival than standard chemotherapy in immunoglobulin-light-chain (AL) amyloidosis, but these two strategies have not been compared in a randomized study. METHODS: We conducted a randomized trial comparing high-dose intravenous melphalan followed by autologous hematopoietic stem-cell rescue with standard-dose melphalan plus high-dose dexamethasone in patients with AL amyloidosis. Patients (age range, 18 to 70 years) with newly diagnosed AL amyloidosis were randomly assigned to receive intravenous high-dose melphalan plus autologous stem cells or oral melphalan plus oral high-dose dexamethasone. RESULTS: Fifty patients were enrolled in each group. The results were analyzed on an intention-to-treat basis, with overall survival as the primary end point. After a median follow-up of 3 years, the estimated median overall survival was 22.2 months in the group assigned to receive high-dose melphalan and 56.9 months in the group assigned to receive melphalan plus high-dose dexamethasone (P=0.04). Among patients with high-risk disease, overall survival was similar in the two groups. Among patients with low-risk disease, there was a nonsignificant difference between the two groups in overall survival at 3 years (58% in the group assigned to receive high-dose melphalan vs. 80% in the group assigned to receive melphalan plus high-dose dexamethasone; P=0.13). CONCLUSIONS: The outcome of treatment of AL amyloidosis with high-dose melphalan plus autologous stem-cell rescue was not superior to the outcome with standard-dose melphalan plus dexamethasone. (ClinicalTrials.gov number, NCT00344526 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gertz, M. A., Comenzo, R., Falk, R. H., Fermand, J. P., Hazenberg, B. P., Hawkins, P. N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., et al. (2005) · American Journal of Hematology · doi:10.1002/ajh.20381 · Cited by 1,428
Self-citationTables of the number of patients required in clinical trials using the logrank test
Freedman, L. S. (1982) · Statistics in Medicine · doi:10.1002/sim.4780010204 · Cited by 718
Kyle, R. A., Gertz, M. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Lacy, M. Q., & Therneau, T. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361702 · Cited by 688
Katzmann, J. A., Clark, R. J., Abraham, R. S., Bryant, S. C., Lymp, J. F., Bradwell, A. R., & Kyle, R. A. (2002) · PubMed · Cited by 620
Katzmann, J. A., Clark, R. J., Abraham, R. S., Bryant, S., Lymp, J. F., Bradwell, A. R., & Kyle, R. A. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.9.1437 · Cited by 620
Skinner, M., Sanchorawala, V., Seldin, D. C., Dember, L. M., Falk, R. H., Berk, J. L., Anderson, J. J., O'Hara, C., Finn, K. T., Libbey, C. A., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-2-200401200-00008 · Cited by 618
Lachmann, H. J., Gallimore, R., Gillmore, J. D., Carr‐Smith, H. D., Bradwell, A. R., Pepys, M. B., & Hawkins, P. N. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04433.x · Cited by 435
Skinner, M., Anderson, J. J., Simms, R. W., Falk, R. H., Wang, M., Libbey, C. A., Jones, L. A., & Cohen, A. S. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)89487-9 · Cited by 370
Autologous stem cell transplantation for primary systemic amyloidosis
Comenzo, R. L., & Gertz, M. A. (2002) · Blood · doi:10.1182/blood.v99.12.4276 · Cited by 357
Dispenzieri, A., Kyle, R. A., Lacy, M. Q., Therneau, T. M., Larson, D. R., Plevak, M. F., Rajkumar, S. V., Fonseca, R., Greipp, P. R., Witzig, T. E., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4192 · Cited by 239
Stem cell transplantation for the management of primary systemic amyloidosis
Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Gastineau, D. A., Chen, M. G., Ansell, S. M., Inwards, D. J., Micallef, I. N. M., Tefferi, A., & Litzow, M. R. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01208-1 · Cited by 160
Dispenzieri, A., Lacy, M. Q., Kyle, R. A., Therneau, T. M., Larson, D. R., Rajkumar, S. V., Fonseca, R., Greipp, P. R., Witzig, T. E., Lust, J. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3350 · Cited by 159
ON THE RELATIONSHIP BETWEEN RESPONSE TO TREATMENT AND SURVIVAL TIME
Buyse, M. E., & Piedbois, P. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19961230)15:24<2797::aid-sim290>3.0.co;2-v · Cited by 133
Outcome of autologous stem cell transplantation for AL amyloidosis in the UK
Goodman, H. J. B., Gillmore, J. D., Lachmann, H. J., Wechalekar, A. D., Bradwell, A. R., & Hawkins, P. N. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06204.x · Cited by 87
Gertz, M. A., Blood, E., Vesole, D. H., Abonour, R., Lazarus, H. M., & Greipp, P. R. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704539 · Cited by 48
“Full length, midi, or mini”: a fashion statement for transplants in myeloma
Vesole, D. H. (2003) · Blood · doi:10.1182/blood-2003-08-2910 · Cited by 7
Cited by
Wechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01274-x · Cited by 994
Bozkurt, B., Colvin, M., Cook, J., Cooper, L. T., Deswal, A., Fonarow, G. C., Francis, G. S., Lenihan, D., Lewis, E. F., McNamara, D. M., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000455 · Cited by 891
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S. O., Palladini, G., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 552
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
Leung, N., Bridoux, F., Hutchison, C. A., Nasr, S. H., Cockwell, P., Fermand, J.-P., Dispenzieri, A., Song, K. W., & Kyle, R. A. (2012) · Blood · doi:10.1182/blood-2012-07-445304 · Cited by 548
Self-citationAmyloidosis: Pathogenesis and New Therapeutic Options
Merlini, G., Seldin, D. C., & Gertz, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2271 · Cited by 509
Metadata
- Authors
- Jaccard, A., Moreau, P., Leblond, V., Leleu, X., Benboubker, L., Hermine, O., Recher, C., Asli, B., Lioure, B., Royer, B., Jardin, F., Bridoux, F., Grosbois, B., Jaubert, J., Piette, J.-C., Ronco, P., Quet, F., Cogne, M., & Fermand, J.-P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-13
- Volume
- 357
- Issue
- 11
- Pages
- 1083-1093
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2033793452
- Cited by
- 519
- References
- 16
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.